 -Phase 1a trial achieved primary objective of safety and tolerability -PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases -PT101 maintained selectivity for regulatory T cells at all doses tested -Phase 1a2b clinical trial in ulcerative colitis expected to start mid-2021 and Phase 2 clinical trial in systemic lupus erythematosus expected to start second half 2021 -Phase 1a results to be presented in a conference call scheduled today at 8:30 a.m. ET 